PROTAC shows efficacy against castration-resistant prostate cancer in preclinical studies
An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumor burden in mice bearing human castration-resistant prostate cancer, according to data presented ...
Apr 5, 2017
0
1